An Unexpected Intriguing Effect of Toll-Like Receptor Regulator RP105 (CD180) on Atherosclerosis Formation With Alterations on B-Cell Activation | Zendy

Jacco C. Karper | Zendy; Saskia C.A. de Jager | Zendy; M.M. Ewing | Zendy; Margreet R. de Vries | Zendy; Ilze Bot | Zendy; Peter J. van Santbrink | Zendy; Anke Redeker | Zendy; Ziad Mallat | Zendy; Christoph J. Binder | Zendy; Ramon Arens | Zendy; J. Wouter Jukema | Zendy; Johan Kuiper | Zendy; Paul H.A. Quax | Zendy

Open Access

An Unexpected Intriguing Effect of Toll-Like Receptor Regulator RP105 (CD180) on Atherosclerosis Formation With Alterations on B-Cell Activation

Author(s) -

Jacco C. Karper,

Saskia C.A. de Jager,

M.M. Ewing,

Margreet R. de Vries,

Ilze Bot,

Peter J. van Santbrink,

Anke Redeker,

Ziad Mallat,

Christoph J. Binder,

Ramon Arens,

J. Wouter Jukema,

Johan Kuiper,

Paul H.A. Quax

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301882

Subject(s) - tlr4 , microbiology and biotechnology , toll like receptor , inflammation , receptor , proinflammatory cytokine , b cell , immunology , foam cell , ldl receptor , bone marrow , myeloid , cell , biology , lipoprotein , chemistry , antibody , immune system , endocrinology , innate immune system , cholesterol , biochemistry

In atherosclerosis, Toll-like receptors (TLRs) are traditionally linked to effects on tissue macrophages or foam cells. RP105, a structural TLR4 homolog, is an important regulator of TLR signaling. The effects of RP105 on TLR signaling vary for different leukocyte subsets known to be involved in atherosclerosis, making it unique in its role of either suppressing (in myeloid cells) or enhancing (in B cells) TLR-regulated inflammation in different cell types. We aimed to identify a role of TLR accessory molecule RP105 on circulating cells in atherosclerotic plaque formation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research